Trials / Completed
CompletedNCT01264692
Essential Hypertension
A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 196 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-280778 | 10 mg once daily for 28 ± 2 days |
| DRUG | Placebo | Placebo oral capsules matching ACT-280778 |
| DRUG | Amlodipine | 10 mg once daily for 28 ± 2 days |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-01-01
- Completion
- 2012-02-01
- First posted
- 2010-12-22
- Last updated
- 2018-09-27
Locations
18 sites across 2 countries: Israel, Serbia
Source: ClinicalTrials.gov record NCT01264692. Inclusion in this directory is not an endorsement.